2 not yet recruiting. 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Not yet recruiting 2 |
Follow RCC: new trials by email Literature Review of RCC trials Research Report on RCC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors. Signatera Genome ultra-sensitive ctDNA blood test - NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer) | Not applicable | Not yet recruiting | Natera, Inc. | 920 | 2027-01-01 | 2026-10-27 |
| A Prospective Registry Study of Stereotactic Ablative Radiotherapy (SABR) for Oligometastatic/Oligometastatic Renal Cell Carcinoma Stereotactic Ablative Radiotherapy (SABR) - Renal Cell Carcinoma, RCC | Not applicable | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 60 | 2024-09-01 | 2024-09-19 |
Carcinoma, Renal Cell (2) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Kidney Neoplasms (1) · Melanoma (1)
Adenocarcinoma (2) · Carcinoma (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Kidney Diseases (2) · Male Urogenital Diseases (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Glandular and Epithelial (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Urologic Diseases (2) · Urologic Neoplasms (2) · Bronchial Neoplasms (1)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Natera, Inc. (1)
Glenn Hanna, MD (1)